- Strong demand from biotechs (first approval decision made and public, Parley Neurotech), we're talking several dozens with $5-300m in funding each - Clinics

- Strong demand from biotechs (first approval decision made and public, Parley Neurotech), we're talking several dozens with $5-300m in funding each - Clinics a bit more lagging, because licensing takes up to 90 days; in a few weeks we hopefully see the first clinic - Business models: I'd personally be very excited about open-sourcing phase-1 assets to encourage further development to better drugs by more people - Yes, this was an explicit hope from the geroscience community to address gaps e.g. in frailty, age-induces diseases with multiple possible endpoints - No explicit rules on telehealth, but administration needs to be in Montana under a brick-and-mortar clinic; telehealth probably possible within those limits